| [1] |
廖洪斐，余进海. 甲状腺相关性眼病治疗现状[J]. 中华眼科杂志，2022，58(8)：635－640.
|
| [2] |
Yin X, Latif R, Bahn R, et al. Genetic profiling in Graves′ disease: further evidence for lack of a distinct genetic contribution to Graves′ ophthalmopathy[J]. Thyroid, 2012, 22(7): 730－736.
|
| [3] |
Khong JJ, Wang LY, Smyth GK, et al. Differential gene expression profiling of orbital adipose tissue in thyroid orbitopathy[J]. Invest Ophthalmol Vis Sci, 2015, 56(11): 6438－6447.
|
| [4] |
Rotondo DG, Bucci I, Lanzolla G, et al. Genetic profiling of orbital fibroblasts from patients with Graves′ orbitopathy[J]. J Clin Endocrinol Metab, 2021, 106(5): e2176－e2190.
|
| [5] |
Zhu L, Li S, He S, et al. The critical role of m(6)A methylation in the pathogenesis of Graves′ ophthalmopathy[J]. Eye Vis (Lond), 2020, 7(1): 55.
|
| [6] |
Virakul S, Somparn P, Pisitkun T, et al. Integrative analysis of proteomics and DNA methylation in orbital fibroblasts from Graves′ ophthalmopathy[J]. Front Endocrinol, 2020, 11: 619989.
|
| [7] |
Xin Z, Hua L, Shi TT, et al. A genome－wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves′ orbitopathy[J]. J Endocrinol Invest, 2018, 41(6): 719－727.
|
| [8] |
Kozlowski E, Wasserman GA, Morgan M, et al. The RNA uridyltransferase Zcchc6 is expressed in macrophages and impacts innate immune responses[J]. PLoS One, 2017, 12(6): e0179797.
|
| [9] |
Xin Z, Hua L, Yang YL, et al. A Pathway analysis based on genome－wide DNA methylation of Chinese patients with Graves′ orbitopathy[J]. Biomed Res Int, 2019, PMID: 9565794.
|
| [10] |
Wang X, Liu W, Rui Z, et al. Immunotherapy with a biologically active ICAM－1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves′ disease[J]. Endokrynol Pol, 2021, 72(6): 592－600.
|
| [11] |
Brooks J, Watson A, Korcsmaros T. Omics approaches to identify potential biomarkers of inflammatory diseases in the focal adhesion complex[J]. Genomics Proteomics Bioinformatics, 2017, 15(2): 101－109.
|
| [12] |
Shi TT, Hua L, Xin Z, et al. Identifying and validating genes with DNA methylation data in the context of biological network for Chinese patients with Graves′ orbitopathy[J]. Int J Endocrinol, 2019, PMID: 6212681.
|
| [13] |
Matsui M, Corey DR. Non－coding RNAs as drug targets[J]. Nat Rev Drug Discov, 2017, 16(3): 167－179.
|
| [14] |
Cech TR, Steitz JA. The noncoding RNA revolution－trashing old rules to forge new ones[J]. Cell, 2014, 157(1): 77－94.
|
| [15] |
Li K, Du Y, Jiang BL, et al. Increased microRNA－155 and decreased microRNA－146a may promote ocular inflammation and proliferation in Graves′ ophthalmopathy[J]. Med Sci Monit, 2014, 20: 639－643.
|
| [16] |
Woeller CF, Roztocil E, Hammond C, et al. TSHR Signaling stimulates proliferation through PI3K/Akt and induction of miR－146a and miR－155 in thyroid eye disease orbital fibroblasts[J]. Invest Ophthalmol Vis Sci, 2019, 60(13): 4336－4345.
|
| [17] |
Wang N, Chen FE, Long ZW. Mechanism of MicroRNA－146a/Notch2 signaling regulating IL－6 in Graves ophthalmopathy[J]. Cell Physiol Biochem, 2017, 41(4): 1285－1297.
|
| [18] |
Jang SY, Chae MK, Lee JH, et al. Role of miR－146a in the regulation of inflammation in an in vitro model of Graves′ orbitopathy[J]. Invest Ophthalmol Vis Sci, 2016, 57(10): 4027－4034.
|
| [19] |
Jang SY, Park SJ, Chae MK, et al. Role of microRNA－146a in regulation of fibrosis in orbital fibroblasts from patients with Graves′ orbitopathy[J]. Br J Ophthalmol, 2018, 102(3): 407－414.
|
| [20] |
Liu W, Ma C, Li HY, et al. MicroRNA－146a downregulates the production of hyaluronic acid and collagen Ⅰ in Graves′ ophthalmopathy orbital fibroblasts[J]. Exp Ther Med, 2020, 20(5): 38.
|
| [21] |
Wei H, Guan M, Qin Y, et al. Circulating levels of miR－146a and IL－17 are significantly correlated with the clinical activity of Graves′ ophthalmopathy[J]. Endocr J, 2014, 61(11): 1087－1092.
|
| [22] |
Ortega－Campos SM, García－Heredia JM.The multitasker protein: a look at the multiple capabilities of NUMB[J]. Cells, 2023, 12(2): 333.
|
| [23] |
Hu ZJ, He JF, Li KJ, et al. Decreased microRNA－146a in CD4+T cells promote ocular inflammation in thyroid－associated ophthalmopathy by targeting NUMB[J]. Eur Rev Med Pharmacol Sci, 2017, 21(8): 1803－1809.
|
| [24] |
杨文娟，班胜刚，何剑峰. 甲状腺相关眼病患者外周血单个核细胞中微小RNA－146a的异常表达及意义[J]. 眼科新进展，2012，32(5)：414－417.
|
| [25] |
Martínez－Hernández R, Sampedro－Núňez M, Serrano－Somavilla A, et al. A MicroRNA signature for evaluation of risk and severity of autoimmune thyroid diseases[J]. J Clin Endocrinol Metab, 2018, 103(3): 1139－1150.
|
| [26] |
Lee JY, Yun M, Paik JS, et al. PDGF－BB enhances the proliferation of cells in human orbital fibroblasts by suppressing PDCD4 expression via up－regulation of microRNA－21[J]. Invest Ophthalmol Vis Sci, 2016, 57(3): 908－913.
|
| [27] |
Tong BD, Xiao MY, Zeng JX, et al. MiRNA－21 promotes fibrosis in orbital fibroblasts from thyroid－associated ophthalmo－pathy[J]. Mol Vis, 2015, 21: 324－334.
|
| [28] |
Hammond CL, Roztocil E, Gonzalez MO, et al. MicroRNA－130a is elevated in thyroid eye disease and increases lipid accumulation in fibroblasts through the suppression of AMPK[J]. Invest Ophthalmol Vis Sci, 2021, 62(1): 29.
|
| [29] |
Wu Y, Guan S, Ge Y, et al. Cigarette smoke promotes chronic obstructive pulmonary disease (COPD) through the miR－130a/Wnt1 axis[J]. Toxicol In Vitro, 2020, 65: 104770.
|
| [30] |
Lin Q, Gao Z, Alarcon RM, et al. A role of miR－27 in the regulation of adipogenesis[J]. FEBS J, 2009, 276(8): 2348－2358.
|
| [31] |
Jang SY, Chae MK, Lee JH, et al. MicroRNA－27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves′ orbitopathy[J]. PLoS One, 2019, 14(8): e0221077.
|
| [32] |
Shi XE, Li YF, Jia L, et al. MicroRNA－199a－5p affects porcine preadipocyte proliferation and differentiation[J]. Int J Mol Sci, 2014, 15(5): 8526－8538.
|
| [33] |
Gao Y, Cao Y, Cui X, et al. miR－199a－3p regulates brown adipocyte differentiation through mTOR signaling pathway[J]. Mol Cell Endocrinol, 2018, 476: 155－164.
|
| [34] |
Craps J, Joris V, Baldeschi L, et al. miR－199a downregulation as a driver of the NOX4/HIF－1α/VEGF－A pathway in thyroid and orbital adipose tissues from Graves′ patients[J]. Int J Mol Sci, 2021, 23(1): 153.
|
| [35] |
Lanzolla G, Marinò M, Marcocci C．Selenium in the treatment of Graves′ hyperthyroidism and eye disease[J]. Front Endocrinol (Lausanne), 2020, 11: 608428.
|
| [36] |
Thiel J, Alter C, Luppus S, et al. MicroRNA－183 and microRNA－96 are associated with autoimmune responses by regulating T cell activation[J]. J Autoimmun, 2019, 96: 94－103.
|
| [37] |
Fuentes－Calvo I, Blázquez－Medela AM, Eleno N, et al. H－Ras isoform modulates extracellular matrix synthesis, proliferation, and migration in fibroblasts[J]. Am J Physiol Cell Physiol, 2012, 302(4): C686－C697.
|
| [38] |
Tan J, Tong BD, Wu YJ, et al. MicroRNA－29 mediates TGFβ1－induced extracellular matrix synthesis by targeting wnt/β－catenin pathway in human orbital fibroblasts[J]. Int J Clin Exp Pathol, 2014, 7(11): 7571－7577.
|
| [39] |
Tang W, Lv Q, Huang X, et al. MiR－143 Targets IGF－1R to suppress autoimmunity in thyroid－associated ophthalmopathy[J]. J Inflamm Res, 2022, 15: 1543－1554.
|
| [40] |
Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms[J]. Br J Ophthalmol, 2016, 100(1): 142－150.
|
| [41] |
Zhang L, Masetti G, Colucci G, et al. Combining micro－RNA and protein sequencing to detect robust biomarkers for Graves′ disease and orbitopathy[J]. Sci Rep, 2018, 8(1): 8386.
|
| [42] |
Wu L, Li L, Liang Y, et al. Identification of differentially expressed long non－coding RNAs and mRNAs in orbital adipose/connective tissue of thyroid－associated ophthalmopathy[J]. Genomics, 2021, 113(2): 440－449.
|
| [43] |
Wang N, Hou SY, Qi X, et al. LncRNA LPAL2/miR－1287－5p/EGFR axis modulates TED－derived orbital fibroblast activation through cell adhesion factors[J]. J Clin Endocrinol Metab, 2021, 106(8): e2866－e2886.
|
| [44] |
Wu L, Zhou R, Diao J, et al. Differentially expressed circular RNAs in orbital adipose/connective tissue from patients with thyroid－associated ophthalmopathy[J]. Exp Eye Res, 2020, 196: 108036.
|
| [45] |
Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language？[J] Cell, 2011, 146(3): 353－358.
|
| [46] |
Yue Z, Mou P, Chen S, et al. A novel competing endogenous RNA network associated with the pathogenesis of Graves′ ophthalmopathy[J]. Front Genet, 2021, 12: 795546.
|
| [47] |
Yue Z, Tong F, Zeng C, et al. Identification of tRNA－related fragments and their potential regulatory effects in thyroid－associated ophthalmopathy[J]. Front Genet, 2022, 13: 878405.
|
| [48] |
Zhang Y, Sun Z, Jia J, et al. Overview of histone modification[J]. Adv Exp Med Biol, 2021, 1283: 1－16.
|
| [49] |
Matheis N, Lantz M, Grus FH, et al. Proteomics of orbital tissue in thyroid－associated orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(12): E1523－ E1530.
|
| [50] |
Ekronarongchai S, Palaga T, Saonanon P, et al. Histone deacetylase 4 controls extracellular matrix production in orbital fibroblasts from Graves′ ophthalmopathy patients[J]. Thyroid, 2021, 31(10): 1566－1576.
|